Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LO-BOT: BOTOX in Overactive Bladder
NCT03052764Phase 4Completed
- Sponsor
- Allergan
- Start
- Dec 2016
- Primary completion
- Dec 2018
- Modality
- Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in overactive bladder (OAB) and urinary incontinence (UI) comparing BOTOX 100 U with Placebo (2 arms). Primary endpoint: Change From Baseline in Daily Average Number of Urinary Incontinence Episodes at 12 weeks. Started Dec 2016; status: completed.
02
Drugs
onabotulinumtoxinA
03
Conditions
overactive bladder (OAB)urinary incontinence (UI)
Beyond the preview
Go deeper on NCT03052764.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03052764.